SS-31 Results Timeline: What Studies Measured, and When

The short answer on timing

Questions about how long SS-31 "takes to work" assume a body of human trial data organised around weeks of follow-up. For the papers summarised on this page, that body of data is thin. A 2025 review of elamipretide described the compound's structure, mechanism of action and therapeutic potential across disease contexts rather than reporting a fixed timeline of clinical effect (PMID 39940712), and a 2026 review of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance examined safety and efficacy claims made for peptides that have not completed the standard approval pathway (PMID 41966639). The practical consequence is that a "week 4 / week 8 / week 12" framework cannot be built from this literature. What can be described is the measurement window each study used: the point at which researchers sampled tissue, ran a behavioural test, or read an imaging or biochemical endpoint.

This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision. Nothing below describes doses, schedules, or expected personal outcomes.

What SS-31 is in the published record

SS-31 is also referred to as elamipretide. A 2025 review characterised it as a mitochondria-targeting peptide that interacts with cardiolipin in the inner mitochondrial membrane, and it surveyed the mechanistic and therapeutic literature that has grown around that interaction (PMID 39940712). A 2026 study in cerebral ischemia-reperfusion injury framed its work explicitly around restoring cardiolipin homeostasis and reported that this suppressed ATG5-mediated neuronal autophagy-dependent ferroptosis (PMID 41831680). Because the proposed mechanism sits at the level of membrane lipids and bioenergetics, the endpoints researchers chose tend to be biochemical and cellular first, and functional or behavioural second — which shapes when measurements were taken. For broader background, see the SS-31 overview.

Three measurement timescales in the literature

Rather than a patient-facing timeline, the SS-31 evidence base can be grouped by how quickly the experimental model reaches its endpoint.

1. Cell and tissue endpoints: hours

In vitro injury models compress everything into a single experimental session. A 2025 study using an SS-31 and ferrostatin-1 combination nanoparticle in hypoxia/reoxygenation cardiomyocytes reported reduced ferroptosis through mitochondrial targeting (PMID 39848110). Hypoxia/reoxygenation is an acute insult applied and then read within the same culture experiment, so the "timeline" there is measured in hours, not weeks, and it says nothing about how long a systemic effect might persist in an intact organism.

2. Acute injury models in animals: hours to days

Injury models in rodents typically apply a defined insult and then sample outcomes at set intervals afterwards. A 2023 study reported that elamipretide alleviated pyroptosis in traumatically injured spinal cord by inhibiting cPLA2-induced lysosomal membrane permeabilization (PMID 36609266). A 2026 study of opioid-induced postoperative cognitive dysfunction in aged rats reported that disruption of hippocampal mitochondrial function underlay the cognitive deficit observed after surgery and opioid exposure (PMID 42546889). In designs like these, the biochemical endpoints and the behavioural endpoints sit at different points on the clock — molecular markers are often sampled earlier than the behavioural testing that follows recovery.

3. Chronic exposure and disease models: weeks

Longer models accumulate pathology before and during treatment. A 2021 study reported that the mitochondrial-targeting antioxidant SS-31 suppressed airway inflammation and oxidative stress induced by cigarette smoke (PMID 34221235), a model that requires repeated smoke exposure before readouts are meaningful. A 2021 study in a mouse model of Friedreich ataxia reported SS-31 efficacy via upregulation of frataxin expression (PMID 34387346), an endpoint tied to a genetic disease process rather than to an acute injury. A 2024 nanotechnology study of comprehensive dry eye therapy addressed the ocular surface barrier while targeting inflammation, oxidation and mitochondrial damage together (PMID 38725011), which places its measurements on the timescale of ocular surface recovery rather than minutes.

Timeline table: model type, endpoint class, and measurement window

Why human "week 4, week 8, week 12" data is the missing piece

Human trials of other compounds show what a genuine outcome timeline looks like. A 2024 analysis from SEQUOIA-HCM reported health status outcomes with aficamten — an unrelated small molecule, not a peptide — in obstructive hypertrophic cardiomyopathy (PMID 39217569). That kind of report exists because participants were assessed with validated instruments at prespecified study visits. The SS-31 papers summarised here are not structured that way: they report mechanistic and functional endpoints in models, and the 2026 peptide review noted that safety and efficacy claims for unapproved peptides in performance settings rest on a different and weaker evidentiary footing than approved therapies (PMID 41966639). Any calendar-style expectation drawn from this literature is an extrapolation, not a reported finding.

Reviews that frame the longer arc

Two reviews in the citation set describe why mitochondrial endpoints can move on very different clocks. A 2025 review argued that mitochondrial dysfunction acts as a driver of kidney disease progression, positioning mitochondrial injury as a slow, cumulative process in renal tissue (PMID 40497970). A 2024 review of the bioenergetics of traumatic brain injury described an acute energy crisis followed by long-term consequences for brain plasticity and function (PMID 39243913). Read together, these two reviews illustrate a general point about timing: a biochemical marker can shift long before — or long after — any functional measure changes, which is precisely why researchers separate the two endpoint classes in study design.

How to read timeline claims about SS-31

• Check the organism. A finding in cardiomyocytes reflects hours in a dish, as in the hypoxia/reoxygenation ferroptosis work (PMID 39848110), not a human treatment course.
• Check the endpoint class. Frataxin expression is a molecular readout (PMID 34387346); behavioural cognition testing after surgery is a functional one (PMID 42546889). They rarely move on the same schedule.
• Check the delivery system. Several studies used engineered carriers rather than the free peptide, including a nanoparticle combining SS-31 with ferrostatin-1 (PMID 39848110) and a multi-target dry eye formulation (PMID 38725011), so results are not interchangeable with plain peptide exposure.
• Check whether humans were studied at all. The 2026 peptide review addressed exactly this gap between marketed claims and approved, trial-supported use (PMID 41966639).

Adverse Events in SS-31 Research: What Studies Report

The verified papers summarised here did not provide a consolidated, time-stamped adverse event table for SS-31. The 2026 review of approved and unapproved peptide therapies examined safety alongside efficacy for peptides used in musculoskeletal injury and athletic performance contexts, and it distinguished agents with regulatory approval from those without (PMID 41966639). The 2025 elamipretide review surveyed mechanism and therapeutic potential across indications rather than cataloguing tolerability by week (PMID 39940712). Where preclinical papers reported outcomes — for example reduced pyroptosis after spinal cord injury (PMID 36609266) — those were efficacy endpoints in animals, and animal tolerability does not transfer to human safety expectations.

What this page does and does not establish

What the literature established: elamipretide/SS-31 has been studied as a cardiolipin-targeting mitochondrial peptide (PMID 39940712), with reported effects on ferroptosis after cerebral ischemia-reperfusion (PMID 41831680), airway inflammation and oxidative stress after cigarette smoke exposure (PMID 34221235), and frataxin expression in a Friedreich ataxia model (PMID 34387346). What it did not establish, in this citation set, is a human timeline: no study here reported a schedule of outcomes at four, eight or twelve weeks in people. Readers encountering week-by-week claims elsewhere should ask which paper, which species and which endpoint produced them.

References

• Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential (International Journal of Molecular Sciences, 2025)
• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (Sports Medicine, 2026)
• SS-31@Fer-1 Alleviates ferroptosis in hypoxia/reoxygenation cardiomyocytes via mitochondrial targeting (Biomedicine & Pharmacotherapy, 2025)
• Restoring cardiolipin homeostasis mitigates cerebral ischemia-reperfusion injury by suppressing ATG5-mediated neuronal autophagy-dependent ferroptosis (Journal of Advanced Research, 2026)
• Elamipretide alleviates pyroptosis in traumatically injured spinal cord by inhibiting cPLA2-induced lysosomal membrane permeabilization (Journal of Neuroinflammation, 2023)
• Disruption of hippocampal mitochondrial function underlies opioid-induced postoperative cognitive dysfunction in aged rats (Brain, Behavior, and Immunity, 2026)
• Mitochondrial-Targeting Antioxidant SS-31 Suppresses Airway Inflammation and Oxidative Stress Induced by Cigarette Smoke (Oxidative Medicine and Cellular Longevity, 2021)
• SS-31 efficacy in a mouse model of Friedreich ataxia by upregulation of frataxin expression (Human Molecular Genetics, 2021)
• Comprehensive dry eye therapy: overcoming ocular surface barrier and combating inflammation, oxidation, and mitochondrial damage (Journal of Nanobiotechnology, 2024)
• Mitochondrial Dysfunction: The Silent Catalyst of Kidney Disease Progression (Cells, 2025)
• The bioenergetics of traumatic brain injury and its long-term impact for brain plasticity and function (Pharmacological Research, 2024)
• Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM (Journal of the American College of Cardiology, 2024)